Table 2.
Follow-up period and overall outcomes of active surveillance of low- and intermediate-risk prostate cancer patients
| Variable | Category | Low risk (n = 276) | Intermediate risk (n = 96) |
|---|---|---|---|
| Total follow-up period (yr) | – | 4.9 (2.6–7.8) | 4.1 (2.2, 6.1) |
| Period of active surveillance (yr) | – | 3.0 (1.5–5.6) | 2.7 (1.7, 4.9) |
| Follow-up after treatment (yr) | – | 4.0 (2.2–6.0) | 3.7 (1.5, 5.8) |
| Disease progression | – | 86 (31.2) | 25 (26) |
| Disease progression (categorised) | Histological | 55 (20) | 11 (11.5) |
| Radiological | 17 (6.2) | 3 (3.1) | |
| Biochemical | 14 (5.1) | 11 (11.5) | |
| Definitive treatment | – | 86 (31.2) | 22 (23) |
| Definitive treatment (categorised) | RP | 62 (22.5) | 10 (10.4) |
| EBRT | 21 (7.6) | 10 (10.4) | |
| Brachytherapy | 3 (1.1) | 2 (2.1) | |
| Overall survival probability | 5 yr | 93 (88, 96) | 93 (81, 97) |
| 10 yr | 90 (83, 94) | 80 (50, 93) | |
| Disease progression–free survival probability | 5 yr | 62 (55, 69) | 64 (51, 75) |
| 10 yr | 54 (44, 62) | 64 (51, 75) | |
| Treatment-free survival probability | 5 yr | 63 (55, 69) | 69 (56, 79) |
| 10 yr | 54 (44, 62) | 69 (56, 79) | |
| Biochemical recurrence–free survival probability a | 5 yr | 90 (79, 95) | 100 (–) |
Summary statistics are as follows: n (%), median (interquartile range), or % (95% confidence interval).
EBRT = External beam radiotherapy; RP = Radical prostatectomy.
a
Analysis for patients undergoing active treatment only.